LOS ANGELES, Feb. 26, 2013 /PRNewswire/ -- Quantason, the innovator in screening technologies for the early detection of high-risk breast lesions, has named Dr. Mendelson, as Medical Director.
(Logo: http://photos.prnewswire.com/prnh/20121022/LA97501LOGO)
Dr. Mendelson is Lee F. Rogers Professor of Radiology and Medical Education at the Feinberg School of Medicine, Northwestern University, Section Chief and Fellowship Program Director in Breast and Women’s Imaging at Northwestern Memorial Hospital in Chicago. She is an expert in mammography, breast ultrasound and MRI with current interest in automated volumetric ultrasound scanners. Dr. Mendelson is active in the American College of Radiology (ACR), a member of the Breast Commission where she chairs the Economics Committee and the committee that prepared the first edition of BI-RADS® (Breast Imaging Reporting and Data System) for Ultrasound. She and her committee are currently readying the 2nd edition for publication.
“There is a lot in common between Quantason’s quest to develop a dual-mode active ultrasound technology for the detection and location of high-risk lesions and Dr. Mendelson’s interests in breast diagnosis, image-guided interventional procedures, and adjunctive screening with ultrasound,” said Dr. Edmond Rambod, President and CEO of Quantason and added, “Ellen’s unique expertise as the co-investigator in the multicenter ACRIN 6666 study comparing ultrasound with mammography in high risk women with dense breast tissue and in the comparative lesion detection study performed by handheld transducers versus automated scanners, is invaluable as we share the same views and goals of proactively screening for the early detection of high-risk markers by IDUS”.
“Ellen is widely published and an invited speaker on all aspects of breast imaging. She has co-authored the textbook, The Practice of Breast Ultrasound, is a co-organizer of the annual, The Chicago International Breast Course, and serves as the faculty of the International Breast Ultrasound School”, said Dr. Rambod and summarized, “Ellen brings outstanding medical, scientific and practical experience along with a passion for the earliest, safest and least costly detection of breast high-risk lesions and cancer”. Dr. Mendelson said, “I am pleased and proud to be associated with Quantason in developing a reliable, radiation-free, low-risk, low-cost and accessible automated system to early detect microcalcifications associated with high-risk and carcinoma in situ breast lesions”. She concluded that, “in this era of great controversies in breast cancer detection, we are working to enhance our knowledge and experience by adopting new technologies such as IDUSTM which both utilizes the traditional ultrasound systems and significantly improves their performance in providing a robust method for imaging, diagnosis and screening for early detection and follow-up monitoring”.
About Quantason
Quantason has developed IDUS, a revolutionary, next-generation bi-modal platform which fundamentally changes the utilization of conventional ultrasound as a modality for diagnostic imaging and active screening. Quantason’s patented and patent-pending technology expands the capabilities of conventional ultrasound systems by combining anatomical 2D imaging with proprietary, real-time stimulation sequences to detect, 3D locate, and classify micron-size target(s) - previously conceived outside of ultrasound capabilities - based on their response signature(s). For more information, visit www.quantason.com.
SOURCE Quantason
